TRAJENTA®

Linagliptin

Physicians and T2D patients worldwide rely on more than 10 years of simplicity experience with Trajenta®²

TRAJENTA® (linagliptin) is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:¹

monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
combination therapy with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control

See SmPC for available information on different combinations.

The efficacy and safety of 5 mg linagliptin was evaluated in 8 phase III randomised controlled trials. Linagliptin once daily demonstrated clinically significant improvements in glycaemic control vs placebo or comparator.¹

Long-term cardiovascular and kidney safety profile of TRAJENTA® has been demonstrated in 2 cardiovascular outcome trials.^6-11 As TRAJENTA® is primarily excreted via the bile, it is suitable for a broad range of adults with T2D independent of renal function.¹

TRAJENTA® (linagliptin) dose and administration

The recommended dose of TRAJENTA® for adult patients with T2D is 5 mg once daily, independent of renal and hepatic^# function, BMI, age, ethnicity, background T2D therapy^†, and disease duration.^1,5

The burden of hypoglycaemia in adults

Watch Su Down as she provides an overview of the burden of hypoglycaemia in adults with type 2 diabetes and the clinician and patient barriers to discussing this topic. Su will also share tips and resources for discussing hypoglycaemia with your patients.

Developed and funded by Boehringer Ingelheim

Latest webinars

Key Information

Indications

TRAJENTA® is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control.¹

Active Ingredient

The active ingredient in TRAJENTA® is linagliptin.¹

Unique Convenience

Convenience with always one dose once daily.¹

Safety

TRAJENTA® demonstrated its long-term safety profile across a broad range of T2D patients.^7,10

Footnote

*CARMELINA® included 6,979 patients with albuminuria & previous macrovascular disease, and/or impaired kidney function with or without CV comorbidities. CAROLINA® included 6,033 patients with one or more of the following: a) previous vascular disease, b) evidence of vascular- related end-organ damage, c) age: ≥ 70 years and d) ≥ 2 CV risk factors (smoking, hypertension, T2D duration ≥ 10 years, dyslipidemia).
#Pharmacokinetic studies suggest that no dose adjustment is required for patients with hepatic impairment but clinical experience in such patients is lacking.
†Sulphonylureas and insulin are known to cause hypoglycaemia. Therefore, caution is advised when linagliptin is used in combination with a sulphonylurea and/or insulin. A dose reduction of the sulphonylurea or insulin may be considered.

References

TRAJENTA® (linagliptin) Summary of Product Characteristics. SmPCs available at EMC: www.medicines.org.uk (GB) and https://www.emcmedicines.com/en-GB/northernireland/ (NI).
TRAJENTA® global patient data. Data on File, Boehringer Ingelheim, 16 September 2020.
Sitagliptin Summary of Product Characteristics. SmPCs available at EMC: www.medicines.org.uk (GB) and www.emcmedicines.com/en-GB/northernireland/ (NI).
Alogliptin Summary of Product Characteristics. SmPCs available at EMC: www.medicines.org.uk (GB) and www.emcmedicines.com/en-GB/northernireland/ (NI).
Lajara R, et al. Clin Ther. 2014;36(11):1595–605.
Rosenstock J, et al. Cardiovasc Diabetol. 2018;17:39.
Rosenstock J, et al. JAMA 2019;321:69-79.
Cooper M, et al. Diabetes Obes Metab. 2020;22(7):1062-73
Marx N, et al. Diab Vasc Res. 2015;12:164-74.
Rosenstock J, et al. JAMA. 2019;322(12):1155–1166.
Espeland MA, et al. Diabetes Obes Metab 2021;23(2):569-80
McGill JB, et al. Diabetes Care. 2013;36:237–44.

PC-GB-106988 V2

February 2023